Search results for "leishmania"

showing 10 items of 182 documents

IL-17A/F in Leishmania major-resistant C57BL/6 mice.

2019

Proinflammatory IL-17 plays an important role in various diseases and defence against extracellular microorganisms. Healing of leishmaniasis is promoted by Th1/Tc1 cells, whereas Th2/Treg are associated with worsened disease outcome. In addition, high expression of IL-17A in Leishmania-susceptible BALB/c and artificial overexpression of IL-17A in T cells in resistant C57BL/6 mice worsened disease outcome. Since C57BL/6 mice lacking only IL-17A exhibited no phenotype, and IL-17A and IL-17F share similar receptors, but differentially regulate chemokine secretion, we studied mice lacking both IL-17A and IL-17F (IL-17A/F-/- ) in infections with Leishmania major. Interestingly, lesion volumes an…

0301 basic medicineC57BL/6CD4-Positive T-LymphocytesMaleDermatologyBiochemistryProinflammatory cytokineLesion030207 dermatology & venereal diseases03 medical and health sciencesMice0302 clinical medicineTh2 CellsmedicineAnimalsSecretionLeishmania majorReceptorMolecular BiologyIntraepithelial LymphocytesLeishmaniasisCrosses GeneticLeishmaniaMice Inbred BALB CbiologyInterleukin-17Th1 Cellsbiology.organism_classificationPhenotypeMice Inbred C57BL030104 developmental biologyPhenotypeChemokine secretionImmunologyDisease ProgressionCytokinesFemalemedicine.symptomExperimental dermatology
researchProduct

Exosome secretion by Leishmania infantum modulate the chemotactic behavior and cytokinic expression creating an environment permissive for early infe…

2019

Abstract In recent years, several studies demonstrated the role of exosomes in intercellular communications, several Leishmania species belonging to subgenera Leishmania and Viannia have been demonstrated to release exosomes, and their role in parasite-macrophage interactions and in leishmaniasis development has been investigated. However, the release of exosomes by Leishmania infantum has not been studied so far. The aim of this study was to isolate and characterize L. infantum exosomes, and to investigate the biological activity of these exosomes in macrophage cultures. To this end, exosomes were collected from both amastigote and promastigote L. infantum conditioned medium by ultracentri…

0301 basic medicineCytokines production; Exosomes; Leishmania infantum030231 tropical medicineImmunologyGene ExpressionBiologyExosomesExosomeMicrobiology03 medical and health sciences0302 clinical medicineImmune systemparasitic diseasesMacrophageHumansHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsLeishmania infantumAmastigoteCytokineHSP70 Heat-Shock ProteinCytokines productionChemotaxisInterleukin-18InterleukinChemotaxiGeneral MedicineU937 Cells030108 mycology & parasitologybiology.organism_classificationLeishmaniaMicrovesiclesInterleukin-10ExosomeHSP90 Heat-Shock ProteinInfectious DiseasesCytokinesParasitologyLeishmania infantumHumanExperimental parasitology
researchProduct

In silico prediction of Leishmania major -specific CD8+ epitopes

2017

Infections with Leishmania (L.) major induce protective IFN-γ-dependent Th1/Tc1 immunity in C57BL/6 mice as well as in immunocompetent humans. Even though antigen-specific immunity provides lifelong immunity against reinfection, a vaccine against this pathogen does not yet exist. Here, we compared the results obtained from in silico predictions of murine CD8-specific L. major peptides using the algorithm SYFPEITHI with the number and predicted affinity of known proteins/peptides. Our results indicate that the majority of "immunodominant" epitopes of L. major have not been identified so far; thus, computer-based prediction algorithms may aid the development of an effective vaccine.

0301 basic medicineIn silicoDermatologyComputational biologyBiologybiology.organism_classificationLeishmaniaBiochemistryEpitope03 medical and health sciencesPrediction algorithms030104 developmental biology0302 clinical medicineImmunityLeishmania majorMolecular BiologyPathogenCD8030215 immunologyExperimental Dermatology
researchProduct

Synthesis and in vitro leishmanicidal activity of novel [1,2,3]triazolo[1,5-a]pyridine salts

2017

Leishmaniasis remains a significant worldwide problem; it is of great interest to develop new drugs to fight this disease. Recently we described some [1,2,3] triazolo[1,5-a] pyridine compounds with significant leishmanicidal activity. The importance of water solubility in drug action made us realise that we could transform non charged triazolopyridines into charged analogues that could increase the degree of water solubility. With this objective we report here the synthesis of novel [1,2,3] triazolo[1,5-a] pyridinium salts 2-7 from triazolopyridines 1, and the study of their in vitro leishmanicidal activity. The activity was tested on Leishmania infantum, Leishmania braziliensis and Leishma…

0301 basic medicineInhibitorGeneral Chemical EngineeringLeishmania donovaniDrug action01 natural sciences03 medical and health scienceschemistry.chemical_compoundparasitic diseasesTriazolopyridinesAmastigoteCytotoxicityImidazolebiologyChronic phases010405 organic chemistryChemistryBinding.Vivo trypanosomicidal activityGeneral Chemistrybiology.organism_classificationLeishmania braziliensisIn vitro0104 chemical sciencesChemistry030104 developmental biologyBiochemistry123-triazolesAntibacterial activityPyridiniumLeishmania infantumDerivativesRSC Advances
researchProduct

Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran

2018

Cutaneous leishmaniasis (CL) is a serious health challenge at the global level due to Leishmania tropica. This study was conducted to evaluate the risk factors associated with anthroponotic CL (ACL) in unresponsive (patient who does not heal and remains with an active lesion, despite receiving two courses of intra-lesional Glucantime along with cryotherapy and one cycle of systemic Glucantime) and responsive patients in a major focus in southeastern Iran. A case-control study was conducted from April 2015 to October 2016 in the southeast of Iran. Patients were recruited in a major ACL focus from unresponsive and responsive cases. These patients were compared for environmental, clinical, and…

0301 basic medicineLeishmania tropicamedicine.medical_treatmentSocial Scienceslcsh:MedicineScarsCryotherapyIranPathology and Laboratory MedicineLogistic regressionPolymerase Chain ReactionGeographical Locations0302 clinical medicineRisk FactorsZoonosesMedicine and Health Scienceslcsh:ScienceLeishmaniasisProtozoansLeishmaniaMultidisciplinaryGeographybiologyEukaryotaInfectious Diseasesmedicine.symptomResearch ArticleNeglected Tropical Diseasesmedicine.medical_specialtyAsiaPatients030106 microbiology030231 tropical medicineLeishmaniasis CutaneousHuman GeographyLesion03 medical and health sciencesSigns and SymptomsCutaneous leishmaniasisDiagnostic MedicineInternal medicineParasitic DiseasesmedicineHumansProtozoan Infectionsbusiness.industrylcsh:ROrganismsHealth Risk AnalysisBiology and Life SciencesOdds ratioDNA ProtozoanTropical Diseasesmedicine.diseasebiology.organism_classificationParasitic ProtozoansConfidence intervalHealth CareAge GroupsLeishmania tropicaCase-Control StudiesPeople and PlacesLesionsEarth SciencesHousingPopulation Groupingslcsh:QbusinessPLOS ONE
researchProduct

Good's syndrome and recurrent leishmaniasis: A case report and review of literature

2020

We report the case of a 56-year-old Caucasian male affected by thymoma and myasthenia gravis that developed recurrent visceral leishmaniasis 11 years after thymectomy. After treatment of each relapse with liposomal amphotericin B the PCR-Leishmania was negative and the patient showed clinical improvement. An immunologic work-up was performed showing lymphopenia with an important decrease in CD4+ T cells (52 cells/μ) and CD4/CD8 ratio (0.2). HIV test was negative. On the basis of previous thymoma and myasthenia gravis and on the basis of the immunological profile a diagnosis of Good's syndrome was made. Since IFNγ plays a main role in the control of Leishmania infection the production of IFN…

0301 basic medicineLeishmaniasiThymomamedicine.medical_treatmentT cellImmunologyLiposomal amphotericin BCase ReportGood's syndromeCD4+ T cell03 medical and health sciences0302 clinical medicinemedicineIntensive care medicinelcsh:Social sciences (General)lcsh:Science (General)LeishmaniasisInternal medicineInfectious diseaseMultidisciplinarybusiness.industryLeishmaniasisImmunotherapymedicine.diseaseLaboratory medicineCD4+ T cellsMyasthenia gravisThymectomy030104 developmental biologyVisceral leishmaniasismedicine.anatomical_structureImmunologylcsh:H1-99business030217 neurology & neurosurgeryCD8IFNγlcsh:Q1-390Heliyon
researchProduct

In vitro antileishmanial activity of trans-stilbene and terphenyl compounds

2016

Leishmaniasis are globally widespread parasitic diseases which often leads to death if left untreated. Currently available drugs present different drawbacks, so there is an urgent need to develop new, safe and cost-effective drugs against leishmaniasis. In this study we tested a small library of trans-stilbene and terphenyl derivatives against promastigote, amastigotes and intramacrophage amastigote forms of Leishmania infantum. Two compounds of the series, the trans-stilbene 3 and the terphenyl 11, presented the best activity and safety profiles. Terphenyl 11 showed a leshmanicidal activity higher than pentostam and the ability to induce apoptosis selectively in Leishmania infantum while s…

0301 basic medicineMacrophageApoptosisPharmacologychemistry.chemical_compoundStilbenesLeishmania infantumProgrammed cell deathbiologyCell CycleGeneral MedicineU937 CellsFlow CytometryInfectious DiseasesTerphenyl CompoundsLeishmania infantumU937 CellHumanTerphenylLeishmaniasiImmunologyAntiprotozoal AgentsContext (language use)Cercopithecus03 medical and health sciencesInhibitory Concentration 50Structure-Activity RelationshipTerphenylTerphenyl Compoundsparasitic diseasesmedicineStructure–activity relationshipAnimalsHumansAmastigoteLeishmaniasis; Programmed cell death; Stilbenes; Terphenyls; Animals; Antiprotozoal Agents; Apoptosis; Cell Cycle; Cercopithecus; Epithelial Cells; Flow Cytometry; Humans; Inhibitory Concentration 50; Leishmania infantum; Macrophages; Microscopy Fluorescence; Stilbenes; Structure-Activity Relationship; Terphenyl Compounds; U937 Cells; Parasitology; ImmunologyEpithelial CellAnimalCercopithecuMacrophagesTerphenylsApoptosiLeishmaniasisEpithelial CellsTerphenyl Compoundmedicine.diseasebiology.organism_classificationIn vitro030104 developmental biologychemistryMicroscopy FluorescenceStilbeneAntiprotozoal AgentImmunologyParasitology
researchProduct

Myeloid cells do not contribute to gender-dependent differences in disease outcome in murine cutaneous leishmaniasis.

2015

Gender-associated differences in the outcome of infections are well known. Apart from behavior-released differences in their incidence, immunological factors also contribute to disease outcome. The underlying mechanisms are often unknown. Here, we show that in murine experimental leishmaniasis, female mice develop larger skin lesions that harbor significantly more parasites, exhibit increased parasite dissemination to visceral organs associated with a shift towards T helper (Th) 2 immunity with increased levels of IL-4. Antigen presenting cells (APC) responsible for T cell priming, such as macrophages or dendritic cells, were not involved in the process. Additionally, in adoptive transfer e…

0301 basic medicineMaleAdoptive cell transferMyeloidStromal cellT cellImmunologyLeishmaniasis CutaneousBiology03 medical and health sciencesMice0302 clinical medicineImmune systemTh2 CellsCutaneous leishmaniasismedicineAnimalsHumansCell LineageMyeloid CellsAntigen-presenting cellTh1-Th2 BalanceCells CulturedCell DifferentiationDendritic cellmedicine.diseaseHormonesMice Inbred C57BLDisease Models Animal030104 developmental biologymedicine.anatomical_structureImmunologyDisease ProgressionFemaleSexDisease SusceptibilityInterleukin-4Stromal Cells030215 immunologyCellular immunology
researchProduct

Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasites

2017

Visceral leishmaniasis (VL) is a neglected tropical disease that affects the poorest communities and can cause substantial morbidity and mortality. Visceral leishmaniasis is characterized by the presence of Leishmania parasites in the spleen, liver and bone marrow, hepatosplenomegaly, pancytopenia, prolonged fever, systemic inflammation and low body mass index (BMI). The factors impacting on the severity of VL are poorly characterized. Here we performed a cross-sectional study to assess whether co-infection of VL patients with intestinal parasites influences disease severity, assessed with clinical and haematological data, inflammation, cytokine profiles and BMI. Data from VL patients was s…

0301 basic medicineMaleIMPACTPhysiologyHepatosplenomegalySystemic inflammationPathology and Laboratory MedicineTHERAPYSeverity of Illness IndexBody Mass Index0302 clinical medicineIntestinal ParasitesBone MarrowZoonosesImmune PhysiologyMedicine and Health SciencesIntestinal Diseases ParasiticHELMINTH INFECTIONSLeishmaniasisImmune ResponseInnate Immune SystembiologyCoinfectionlcsh:Public aspects of medicineASCARIASIS11 Medical And Health SciencesHematologyPancytopenia3. Good healthInfectious DiseasesCytokinesLeishmaniasis Visceralmedicine.symptomLife Sciences & BiomedicineHepatomegalyResearch ArticleNeglected Tropical DiseasesAdultlcsh:Arctic medicine. Tropical medicineAdolescentlcsh:RC955-962030231 tropical medicineImmunology03 medical and health sciencesYoung AdultSigns and SymptomsDONOVANIDiagnostic MedicineTropical MedicineHOOKWORMSeverity of illnessmedicineParasitic DiseasesAnimalsHumansParasitesInflammationScience & TechnologyProtozoan InfectionsINTERFERON-GAMMAbusiness.industryPublic Health Environmental and Occupational HealthTropical diseaseBiology and Life SciencesLeishmaniasislcsh:RA1-127006 Biological SciencesMolecular DevelopmentINTERLEUKIN-10Leishmaniabiology.organism_classificationmedicine.diseaseTropical Diseases030104 developmental biologyVisceral leishmaniasisCross-Sectional StudiesLogistic ModelsCase-Control StudiesCo-InfectionsImmune SystemImmunologySplenomegalyUNDERNUTRITIONParasitologyEthiopiabusinessParasitic Intestinal DiseasesSpleenDevelopmental Biology
researchProduct

Direct-acting antivirals and visceral leishmaniasis: a case report

2019

Abstract Background Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions of the immune system impair the capability to resolve the infection and allow reactivation from sites of latency of the parasite. Case presentation We describe a case of visceral leishmaniasis (VL) that occurred in a patient with chronic hepatitis C treated with direct-acting antiviral drugs (DAA). The hypothesized mechanism is the alteration of protective inflammation mechanisms secondary to DAA therapy. Downregulation of type II an…

0301 basic medicineMaleSofosbuvir030106 microbiologyAntiprotozoal AgentsCase ReportDirect-acting antiviralAntiviral Agentslcsh:Infectious and parasitic diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemAmphotericin BRibavirinHumansMedicinelcsh:RC109-216030212 general & internal medicineLeishmania infantumAgedAntiviral AgentLeishmaniaVisceral Leishmaniasisbiologybusiness.industryCoinfectionRibavirinHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseLeishmaniaHepatitis CInfectious DiseasesVisceral leishmaniasischemistryAntiprotozoal AgentImmunologyCoinfectionVisceral LeishmaniasiLeishmaniasis VisceralLeishmania infantumSofosbuvirbusinessmedicine.drugHumanBMC Infectious Diseases
researchProduct